{'fraction_non_alphanumeric': 0.017241379310344827, 'fraction_numerical': 0.0038314176245210726, 'mean_word_length': 5.792207792207792, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cannabinoid agonist shows promise for treating cannabis dependence

Treatment with a cannabinoid agonist product containing tetrahydrocannabinol (THC) and cannabidiol (CBD) resulted in fewer days of illicit cannabis use compared with placebo in a 12‐week randomized trial of patients with cannabis dependence. Because of the high number of subjects who dropped out of the study, however, researchers stated that more studies are needed to evaluate the potential role of cannabinoid agonist therapy for cannabis dependence.